tiprankstipranks
Trending News
More News >

Cyclopharm’s Technegas Advances Pulmonary Embolism Diagnostics

Cyclopharm’s Technegas Advances Pulmonary Embolism Diagnostics

Cyclopharm Limited (AU:CYC) has released an update.

Confident Investing Starts Here:

Cyclopharm Limited has successfully imaged the first patients in a French clinical trial using its Technegas technology, which aims to improve the detection of recurring pulmonary embolism through advanced imaging techniques. This trial could redefine diagnostic protocols globally and support Cyclopharm’s growth strategy by enhancing the adoption of precision pulmonary diagnostics.

For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App